Indo US Bio-Tech (INDOUS)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 70.17% aligns management with minority shareholders
• ROE of 21.12% and ROCE of 21.15% indicate efficient capital deployment at current levels
• Low debt/equity of 0.32 keeps the balance sheet conservative
• Latest quarter is still profitable: ₹3 Cr net profit on ₹23 Cr sales
• Book value of ₹44.26 provides some downside reference, though price is above it

Concerns

• Profit growth of -40.59% and sales growth of -3.23% show a shrinking business
• Piotroski F-Score of 3/9 indicates weak financial fundamentals
• P/E of 19.55 is expensive for a company with negative growth
• Dividend yield of 0.17% is negligible for a retail income investor

AI Analysis

Looking at Indo US Bio-Tech, my first reaction is caution. A business with sales down 3.23% and profits down 40.59% is not compounding shareholder value. At ₹105.04, market cap ₹290 Cr, I am paying 19.55 times trailing earnings and 2.37 times book value. For a slow/no-growth operation, that is not a bargain. The Piotroski F-Score of 3 out of 9 reinforces my suspicion: the financial health has deteriorated. Positive points: promoter holding of 70.17% aligns owners with shareholders, and debt/equity of 0.32 is reasonable. Return on equity and ROCE both above 21% are impressive on the surface, but if earnings keep shrinking, those figures will fall. Latest quarter sales of ₹23 Cr and net profit of ₹3 Cr suggest margins are still okay, but it is only one quarter. I cannot call this a wonderful business. Agricultural products often lack pricing power, and with no growth in sales, there is no evidence of a durable competitive advantage. Dividend yield of 0.17% means the small shareholder gets no income while waiting. If I owned it, I would ask why profits fell 40% while sales fell only 3%; that points to margin compression or one-time problems. The 52-week range of ₹74.98 to ₹171.20 shows how volatile this small-cap is. At this price, I would not rush in. I need proof of stabilised margins and renewed growth, or a much lower price, before it meets my margin of safety. Even with high ROE, a shrinking company deserves no premium. Let the numbers improve first.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer